Skip to main content
SpringerLink
Log in

Clinical Considerations and Applications in Cardiac Diseases

  • Chapter
Natriuretic Peptides

Abstract

CNH are powerful hormones with important physiological effects. Consequently, by considering their assay only as a marker for cardiac disease may result in a misinterpretation or underestimation of their biological action and of their pathophysiological role in cardiovascular as well as other diseases. In the first part of Chapter 5 (from section 5.1.1 to 5.1.5), some physiological conditions in which the interpretations of increased levels of CNH may be difficult or provoke misunderstanding will be discussed in detail. In particular, the influence of age and sex hormones on circulating levels of CNH will be reviewed (section 5.1.1). As far as the clinical interpretation of variations of circulating levels of CNH is concerned, some important points will be stressed: 1) the pathophysiological and clinical consequence of the progressive resistance to biological actions of CNH in patients with heart failure (section 5.1.3); 2) the inter-relationship between hemodynamic mechanisms and activity of neuro-endocrine system in determining the variation of circulating levels of CNH (section 5.1.4); 3) the clinical relevance of variation of CNH levels (section 5.1.5). The discussion of these points will lay the pathophysiological foundations for better understanding of the second part of this Chapter, which concerns the diagnostic and prognostic role of CNH assay in patients with cardiovascular disease (sections from 5.2 to 5.5).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. De Bold AJ, Ma KKY, Zhang Y et al (2001) The physiological and pathophysiological modulation of the endocrine function of the heart. (Review) Can J Physiol Pharmacol 79:705–714

    PubMed  Google Scholar 

  2. Clerico A (2002) Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: is their assay merely a marker of cardiac disease? (Opinion Article) Clin Chem Lab Med 40:752–760

    PubMed  CAS  Google Scholar 

  3. Ruskoaho H (2003) Cardiac hormones as diagnostic tools in heart failure. (Review) Endocr Rev 24:341–356

    PubMed  CAS  Google Scholar 

  4. de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. (Review) Lancet 362:316–322

    PubMed  Google Scholar 

  5. Clerico A, Emdin M (2004) Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. (Review) Clin Chem 50:33–50

    PubMed  CAS  Google Scholar 

  6. Goetze JP (2004) Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. (Review) Clin Chem 9:1503–1510

    Google Scholar 

  7. Clerico A, Del Ry S, Maffei S et al (2002) Circulating levels of cardiac natriuretic hormones in healthy adult subjects: effects of aging and sex. Clin Chem Lab Med 40:371–377

    PubMed  CAS  Google Scholar 

  8. Redfield MM, Rodeheffer RJ, Jacobsen SJ et al (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40:976–982

    PubMed  CAS  Google Scholar 

  9. Vasan RS, Benjamin EJ, Larson MG et al (2002) Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. JAMA 288:1252–1259

    PubMed  CAS  Google Scholar 

  10. Wang TJ, Larson MG, Levy D et al (2002) Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90:254–258

    PubMed  CAS  Google Scholar 

  11. Friesinger GC (1999) Cardiovascular disease in the elderly. (Review) Cardiol Clin 17:35–49

    Google Scholar 

  12. De Bold AJ, Bruneau BG, Kuroski de Bold ML (1996) Mechanical and neuroendocrine regulation of the endocrine heart. (Review) Cardiovasc Res 31:7–18

    PubMed  Google Scholar 

  13. Kuroski de Bold ML (1999) Estrogen, natriuretic peptides and the renin-angiotensin system. (Review) Cardiovasc Res 41:524–531

    PubMed  CAS  Google Scholar 

  14. Maffei S, Del Ry S, Prontera C, Clerico A (2001) Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci 101:447–453

    PubMed  CAS  Google Scholar 

  15. Sayama H, Nakamura Y, Saito N, Kinoshita M (1999) Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 10:537–540

    PubMed  CAS  Google Scholar 

  16. Ueda R, Yokouchi M, Suzuki T et al (2003) Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med 114:266–270

    PubMed  CAS  Google Scholar 

  17. Giannessi D, Andreassi MG, Del Ry S et al (2001) Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest 24:8–16

    PubMed  CAS  Google Scholar 

  18. Clerico A, Del Ry S, Giannessi D (2000) Measurement of natriuretic cardiac hormones (ANP, BNP, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. (Review) Clin Chem 46:1529–1534

    PubMed  CAS  Google Scholar 

  19. Hammerer-Lercher A, Neubauer E, Muller S et al (2001) Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310:193–197

    PubMed  CAS  Google Scholar 

  20. Prontera C, Emdin M, Zucchelli GC et al (2003) Fully-automated NT-proBNP and IRMA methods for BNP and ANP in heart failure and healthy subjects. (Letter) Clin Chem 49:1552–1554

    PubMed  CAS  Google Scholar 

  21. Clerico A, Prontera C, Emdin M et al (2005) Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma BNP and NT-proBNP concentrations. Clin Chem 51:445–447

    PubMed  Google Scholar 

  22. Clerico A, Caprioli R, Del Ry S, Giannessi D (2001) Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 24:24–30

    PubMed  CAS  Google Scholar 

  23. Ylitalo K, Uusimaa P, Vuolteenaho O et al (1999) Vasoactive peptide release in relation to hemodynamic and metabolic changes during rapid ventricular pacing. Pacing Clin Electrophysiol 22:1064–1070

    PubMed  CAS  Google Scholar 

  24. Clerico A, Iervasi G (1995) Alterations in metabolic clearance of atrial natriuretic peptides in heart failure: how do they relate to the resistance to atrial natriuretic peptides? (Review) J Card Fail 1:323–328

    PubMed  CAS  Google Scholar 

  25. Charloux A, Piquard F, Doutreleau S et al (2003) Mechanisms of renal hyporesponsiveness to ANP in heart failure. (Review) Eur J Clin Invest 33:769–778

    PubMed  CAS  Google Scholar 

  26. Clerico A, Iervasi G, Pilo A (2000) Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. (Review) Curr Drug Metab 1:85–105

    PubMed  CAS  Google Scholar 

  27. Clerico A, Iervasi G (1995) Alterations in metabolic clearance of atrial natriuretic peptides in heart failure: how do they relate to the resistance to atrial natriuretic peptides? J Card Fail 1:323–328

    PubMed  CAS  Google Scholar 

  28. Cody RJ, Atlas SA, Laragh JH et al (1986) Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 78:1362–1374

    PubMed  CAS  Google Scholar 

  29. Saito Y, Nakao K, Nishimura K et al (1987) Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 76:115–124

    PubMed  CAS  Google Scholar 

  30. Komeichi H, Moreau R, Cailmail S et al (1995) Blunted natriuresis and abnormal systemic hemodynamic responses to C-type and brain natriuretic peptides in rats with cirrhosis. J Hepatol 22:319–325

    PubMed  CAS  Google Scholar 

  31. Zeidel ML (2000) Physiological responses to natriuretic hormones. In: Fray JCS, Goodman HM (eds) Handbook of physiology, Section 7, The endocrine system, Volume III: Endocrine regulation of water and electrolyte balance. Oxford University Press, New York, pp 410–435

    Google Scholar 

  32. Iervasi G, Clerico A, Berti S et al (1995) Altered tissue degradation and distribution of atrial natriuretic peptide in patients with idiopathic dilated cardiomyopathy and its relationship with clinical severity of the disease and sodium handling. Circulation 91:2018–2027

    PubMed  CAS  Google Scholar 

  33. Clerico A, Iervasi G, Pilo A (2005) Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. Curr Drug Metab 1:85–105

    Google Scholar 

  34. Apple FS, Panteghini M, Ravkilde J et al (2005) Quality specifications for B-type natriuretic peptide assays. Clin Chem 51:486–493

    PubMed  CAS  Google Scholar 

  35. Panteghini M, Clerico A (2004) Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: the prerequisite for its optimal clinical use. (Review) Clin Lab 50:325–331

    PubMed  CAS  Google Scholar 

  36. Belenky A, Smith A, Zhang B et al (2004) The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 340:163–172

    PubMed  CAS  Google Scholar 

  37. Shimizu H, Masuta K, Aono K et al (2002) Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 316:129–135

    PubMed  CAS  Google Scholar 

  38. Shimizu H, Masuta K, Asada H et al (2003) Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 334:233–239

    PubMed  CAS  Google Scholar 

  39. Trindade PT, Rouleau JL (2001) Vasopeptidase inhibitors: potential role in the treatment of heart failure. (Review) Heart Fail Monit 2:2–7

    PubMed  CAS  Google Scholar 

  40. Sagnella GA (2002) Vasopeptidase inhibitors. (Review) J Renin Angiotensin Aldosterone Syst 3:90–95

    PubMed  CAS  Google Scholar 

  41. Dawson A, Struthers AD (2002) Vasopeptidase inhibitors in heart failure. (Review) J Renin Angiotensin Aldosterone Syst 3:156–159

    PubMed  CAS  Google Scholar 

  42. Floras JS (2002) Vasopeptidase inhibition: a novel approach to cardiovascular therapy. (Review) Can J Cardiol 18:177–182

    PubMed  Google Scholar 

  43. Andreassi MG, Del Ry S, Palmieri C et al (2001) Up-regulation of ‘clearance’ receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur J Heart Fail 3:407–414

    PubMed  CAS  Google Scholar 

  44. Tsunoda K, Mendelsoohn FAO, Sexton PM et al (1988) Decreased atrial natriuretic peptide binding in renal medulla in rats with chronic heart failure. Circ Res 62:155–161

    PubMed  CAS  Google Scholar 

  45. Tsutamoto T, Kanamory T, Morigami N et al (1993) Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 87:70–75

    PubMed  CAS  Google Scholar 

  46. Mukkaddam-Daher S, Tremblay J, Fujio N et al (1996) Alteration of lung atrial natriuretic peptide receptors in genetic cardiomyopathy. Am J Physiol 271:138–145

    Google Scholar 

  47. Kuhn M, Voss M, Mitko D et al (2004) Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure. Cardiovasc Res 64:308–314

    PubMed  CAS  Google Scholar 

  48. Fan D, Bryan PM, Antos LK et al (2004) Downregulation does not mediate natriuretic peptidedependent desensitization of NPR-A or NPR-B: guanylyl cyclase-linked natriuretic peptide receptors do not internalize. Mol Pharmacol (printed online Sept 30, 2004)

    Google Scholar 

  49. Bryan PM, Potter LR (2002) The atrial natriuretic peptide receptor (NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases. J Biol Chem 277:16041–16047

    PubMed  CAS  Google Scholar 

  50. Potter LR, Hunter T (1998) Phosphorylation of the kinase homology domain is essential for activation of the A-type natriuretic peptide receptor. Mol Cell Biol 18:2164–2172

    PubMed  CAS  Google Scholar 

  51. Dessi-Fulgheri P, Sarzani R, Rappelli A (1998) The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J Nephrol 11:296–299

    PubMed  CAS  Google Scholar 

  52. Sarzani R, Strazzullo P, Salvi F et al (2004) Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res 12:351–356

    PubMed  CAS  Google Scholar 

  53. Mehra MR, Uber PA, Park MH et al (2004) Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43:1590–1595

    PubMed  CAS  Google Scholar 

  54. Wang TJ, Larson MG, Levy D et al (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109:594–600

    PubMed  CAS  Google Scholar 

  55. Ahluwalia A, MacAllister RJ, Hobbs AJ (2004) Vascular actions of natriuretic peptides. Cyclic GMP-dependent and-independent mechanisms. Basic Res Cardiol 99:83–89

    PubMed  CAS  Google Scholar 

  56. Drewett JG, Ziegler RJ, Trachte GJ (1990) Neuromodulatory effects of atrial natriuretic factor are independent of guanylate cyclase in adrenergic neuronal pheochromocytoma cells. J Pharmacol Exp Ther 255:497–503

    PubMed  CAS  Google Scholar 

  57. Anand-Srivastava MB, Sairam MR, Cantin M (1988) Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. J Biol Chem 265:8566–8572

    Google Scholar 

  58. Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanisms of disease progression in heart failure. (Review) J Am Coll Cardiol 20:248–254

    PubMed  CAS  Google Scholar 

  59. Benedict CR (1994) Neurohormonal aspects of congestive heart failure. (Review) Cardiol Clin 12:9–23

    PubMed  CAS  Google Scholar 

  60. Emdin M, Passino C, Prontera C et al (2004) Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 42:627–636

    PubMed  CAS  Google Scholar 

  61. Richards AM, Lainchbury JG, Nicholls MG et al (2002) BNP in hormone-guided treatment of heart failure. (Review) Trends Endocrinol Metab 13:151–155

    PubMed  CAS  Google Scholar 

  62. Latini R, Masson S, De Angelis N, Anand I (2002) Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. (Review) J Card Fail 8:288–299

    PubMed  CAS  Google Scholar 

  63. Richards M, Troughton RW (2004) NT-proBNP in heart failure: therapy decisions and monitoring. (Review) Eur J Heart Fail 6:351–354

    PubMed  CAS  Google Scholar 

  64. Bettencourt P (2004) NT-proBNP and BNP: biomarkers for heart failure management. (Review) Eur J Heart Fail 6:359–363

    PubMed  CAS  Google Scholar 

  65. Cowie MR, Mendez GF (2002) BNP and congestive heart failure. (Review) Prog Cardiovasc Dis 44:293–321

    PubMed  CAS  Google Scholar 

  66. Nakamura M, Endo H, Nasu M et al (2002) Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 87:131–135

    PubMed  CAS  Google Scholar 

  67. Kawai K, Hata K, Tanaka K et al (2004) Attenuation of biological compensatory action of cardiac natriuretic peptide system with aging. Am J Cardiol 93:719–723

    PubMed  CAS  Google Scholar 

  68. A report of the American College of Cardiology (2001) American Heart Association Task Force on Practice Guidelines. Evaluation and management of chronic heart failure in the adult. ACC/AHA Practice Guidelines

    Google Scholar 

  69. Remme WJ, Swedberg K (2001) Task Force Report. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22:1527–1560

    PubMed  CAS  Google Scholar 

  70. NICE (2003) Clinical Guideline 5. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care. London, pp 1–44

    Google Scholar 

  71. Bossuyt PM (2003) Study design and quality of evidence. In: Price CP, Christenson RH (eds) Evidence-based laboratory medicine. From principles to outcome. AACC Press, Washington DC, pp 75–92

    Google Scholar 

  72. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ (2004) A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. (Review) Arch Intern Med 164:1978–1984

    PubMed  CAS  Google Scholar 

  73. Logeart D, Saudubray C, Beyne P et al (2002) Comparative values of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Col Cardiol 40:1794–1800

    Google Scholar 

  74. Dokainish H, Zoghbi WA, Lakkis NM et al (2004) Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. Am J Cardiol 93:1130–1135

    PubMed  CAS  Google Scholar 

  75. Williams SG, Ng LL, O’Brien RJ et al (2004) Comparison of plasma N-brain natriuretic peptide, peak oxygen consumption, and left ventricular ejection fraction for severity of chronic heart failure. Am J Cardiol 93:1560–1561

    PubMed  CAS  Google Scholar 

  76. Galvani M, Ferrini D, Ottani T (2004) Natriuretic peptides for risk stratification of patients with acute coronary syndromes. (Review) Eur J Heart Fail 6:327–333

    PubMed  CAS  Google Scholar 

  77. Jernberg T, James S, Lindahl B et al (2004) Natriuretic peptides in unstable coronary artery disease. (Review) Eur Heart J 25:1486–1493

    PubMed  CAS  Google Scholar 

  78. Wiviott SD, de Lemos JA, Morrow DA (2004) Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. (Review) Clin Chim Acta 346:119–128

    PubMed  CAS  Google Scholar 

  79. Kellett J (2004) Prediction of in-hospital mortality by brain natriuretic peptide levels and other independent variables in acutely ill patients with suspected heart disease. Can J Cardiol 20:686–690

    PubMed  Google Scholar 

  80. Kruger S, Graf J, Merx MW et al (2004) Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 147:60–65

    PubMed  CAS  Google Scholar 

  81. Kucher N, Printzen G, Goldhaber SZ (2003) Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 107:2545–2547

    PubMed  CAS  Google Scholar 

  82. ten Wolde M, Tulevski II, Mulder JW et al (2003) Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 107:2082–2084

    PubMed  Google Scholar 

  83. Nagaya N, Nishikimi T, Uematsu M et al (2000) Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102:865–870

    PubMed  CAS  Google Scholar 

  84. Vesely DL (2003) Natriuretic peptides and acute renal failure. (Review) Am J Physiol Renal Physiol 285:F167–177

    PubMed  CAS  Google Scholar 

  85. McCullough PA, Kuncheria J, Mathur VS (2004) Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. (Review) Rev Cardiovasc Med 5:16–25

    PubMed  Google Scholar 

  86. Castillo JR, Zagler A, Carrillo-Jimenez R, Hennekens CH (2004) Brain natriuretic peptide: a potential marker for mortality in septic shock. Int J Infect Dis 8:271–274

    PubMed  CAS  Google Scholar 

  87. Palladini G, Campana C, Klersy C et al (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107:2440–2445

    PubMed  CAS  Google Scholar 

  88. Yasutake H, Seino Y, Kashiwagi M et al (2005) Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 102:259–268

    PubMed  Google Scholar 

  89. Bhalla MA, Chiang A, Epshteyn VA et al (2004) Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 44:1047–1052

    PubMed  CAS  Google Scholar 

  90. Takeda Y, Fukutomi T, Suzuki S et al (2004) Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 94:448–453

    PubMed  CAS  Google Scholar 

  91. Sackett DL, Haynes RB (2002) The architecture of diagnostic research. Br Med J 324:539–541

    CAS  Google Scholar 

  92. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ (2003) Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 41:113–120

    PubMed  Google Scholar 

  93. Sim V, Hampton D, Phillips C et al (2003) The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction-cost-effectiveness in relation to open access echocardiography. Fam Pract 20:570–574

    PubMed  Google Scholar 

  94. Ng LL, Loke I, Davies JE et al (2003) Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail 5:775–782

    PubMed  CAS  Google Scholar 

  95. Fraser CG (2004) Inherent biological variation and reference values. (Review) Clin Chem Lab Med 42:758–764

    PubMed  CAS  Google Scholar 

  96. Cotlove E, Harris EK, Williams GZ (1970) Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 3. Physiological and medical implications. Clin Chem 16:1028–1032

    PubMed  CAS  Google Scholar 

  97. Pagani F, Stefini F, Panteghini M (2003) Biological variation in serum concentrations of Nterminal pro-brain natriuretic peptide (NT-proBNP). (Abstract) Clin Chem 49:A34

    Google Scholar 

  98. Melzi d’Eril GV, Tagnochetti T, Nauti A et al (2003) Biological variation of N-terminal probrain natriuretic peptide in healthy individuals. Clin Chem 49:1554–1555

    PubMed  CAS  Google Scholar 

  99. Wu AH, Smith A, Wieczorek S et al (2003) Biological variation for N-terminal pro-and Btype natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92:628–631

    PubMed  CAS  Google Scholar 

  100. Wu AHB, Smith A (2004) Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 6:355–358

    PubMed  CAS  Google Scholar 

  101. Bruins S, Fokkema MR, Romer JW et al (2004) High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50:2052–2058

    PubMed  CAS  Google Scholar 

  102. Vanderheyden M, Bartunek J, Goethals M (2004) Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 6:261–268

    PubMed  CAS  Google Scholar 

  103. Clerico A, Zucchelli GC, Pilo A, Emdin M (2005) Clinical relevance of biological variation of B-Type natriuretic peptide. (Letter) Clin Chem 51:925–926

    PubMed  CAS  Google Scholar 

  104. Remes J, Miettinen H, Reunanen A, Pyorala K (1991) Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 12:315–321

    PubMed  CAS  Google Scholar 

  105. Fox KF, Cowie MR, Wood DA et al (2001) Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 22:228–236

    PubMed  CAS  Google Scholar 

  106. McQueen MJ (2001) Overview of evidence-based medicine: challenges for evidence-based laboratory medicine. (Review) Clin Chem 47:1536–1546

    PubMed  CAS  Google Scholar 

  107. Bossuyt PM, Reitsma JB, Bruns DE et al (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Chem 49:1–6

    PubMed  CAS  Google Scholar 

  108. Omland T, Aakvaag A, Vik-Mo H (1996) Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 76:232–237

    PubMed  CAS  Google Scholar 

  109. Hobbs FDR, Davis RC, Roalfe AK et al (2002) Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. Br Med J 324:1498–1500

    CAS  Google Scholar 

  110. Cowie MR, Struthers AD, Wood DA et al (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350:1349–1353

    PubMed  CAS  Google Scholar 

  111. Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167

    PubMed  CAS  Google Scholar 

  112. Maisel AS, McCord J, Nowak RM et al (2003) Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41:2010–2017

    PubMed  Google Scholar 

  113. Fisher Y, Filzmaier K, Stiegler H et al (2001) Evaluation of a new, rapid bedside test for qualitative determination of B-type natriuretic peptide. Clin Chem 47:591–594

    Google Scholar 

  114. Apple FS, Trinity E, Steen J et al (2003) BNP test utilization for CHF in community hospital practice. Clin Chim Acta 328:191–193

    PubMed  CAS  Google Scholar 

  115. Bay M, Kirk V, Parner J et al (2003) NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 89:150–154

    PubMed  CAS  Google Scholar 

  116. McLean AS, Tang B, Nalos M et al (2003) Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients. Anaesth Intensive Care 31:21–27

    PubMed  CAS  Google Scholar 

  117. Richards AM, Nicholls MG, Yandle TG et al (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97:1921–1929

    PubMed  CAS  Google Scholar 

  118. Yasue H, Yoshimura M, Sumida H et al (1994) Localization and mechanism of secretion of Btype natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195–203

    PubMed  CAS  Google Scholar 

  119. Nakagawa O, Ogawa Y, Itoh H et al (1995) Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 96:1280–1287

    PubMed  CAS  Google Scholar 

  120. Vasan RS, Benjamin EJ, Levy D (1995) Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 26:1565–1574

    PubMed  CAS  Google Scholar 

  121. Bonow R, Udelson JE (1992) Left ventricular diastolic dysfunction as a cause of congestive heart failure. Ann Intern Med 117:502–510

    PubMed  CAS  Google Scholar 

  122. Grodecki PV, Klein AL (1993) Pitfalls in the echo-Doppler assessment of diastolic dysfunction. Echocardiography 10:213–234

    PubMed  CAS  Google Scholar 

  123. Suzuki T, Yamaoki K, Nakajima O et al (2000) Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels. Jpn Heart J 41:205–214

    PubMed  CAS  Google Scholar 

  124. Maisel AS, Koon J, Krishnaswamy P et al (2001) Utility of B-natriuretic peptide as a rapid, pointof-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 141:367–374

    PubMed  CAS  Google Scholar 

  125. Lubien E, DeMaria A, Krishnaswamy P et al (2002) Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 105:595–601

    PubMed  CAS  Google Scholar 

  126. Vanderheyden M, Goethals M, Verstreken S et al (2004) Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 44:2349–2354

    PubMed  CAS  Google Scholar 

  127. Hayakawa H, Komada Y, Hirayama M et al (2001) Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 37:4–9

    PubMed  CAS  Google Scholar 

  128. Ono M, Tanabe K, Asanuma T et al (2001) Doppler echocardiography-derived index of myocardial performance (TEI index): comparison with brain natriuretic peptide levels in various heart diseases. Jpn Circ J 65:637–642

    PubMed  CAS  Google Scholar 

  129. Prontera C, Emdin M, Zucchelli GC et al (2004) Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay of the N-terminal fragment of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 42:37–44

    PubMed  CAS  Google Scholar 

  130. Panteghini M, Clerico A (2004) Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: the prerequisite for its optimal clinical use. Clin Lab 50:325–331

    PubMed  CAS  Google Scholar 

  131. Apple S, Panteghini M, Ravkilde J et al (2005) Quality specifications for B-type natriuretic peptide assays. Clin Chem 51:486–493

    PubMed  CAS  Google Scholar 

  132. Clerico A, Prontera C, Emdin M et al (2005) Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma BNP and NT-proBNP concentrations. Clin Chem 51:445–447

    PubMed  Google Scholar 

  133. Wright SP, Doughty RN, Pearl A et al (2003) Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 42:1793–1800

    PubMed  CAS  Google Scholar 

  134. Horio T, Shimada K, Kohno M et al (1993) Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty. Am Heart J 126:293–299

    PubMed  CAS  Google Scholar 

  135. Morita E, Yasue H, Yoshimura M et al (1993) Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82–91

    PubMed  CAS  Google Scholar 

  136. Arakawa N, Nakamura M, Aoki H, Hiramori K (1994) Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology 85:334–340

    PubMed  CAS  Google Scholar 

  137. Uusimaa P, Ruskoaho H, Vuolteenaho O et al (1999) Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. Int J Cardiol 69:5–14

    PubMed  CAS  Google Scholar 

  138. Omland T, Aakvaag A, Bonarjee VV et al (1996) Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93:1963–1969

    PubMed  CAS  Google Scholar 

  139. Panteghini M, Cuccia C, Bonetti G et al (2003) Rapid determination of brain natriuretic peptide in patients with acute myocardial infarction. Clin Chem Lab Med 41:164–168

    PubMed  CAS  Google Scholar 

  140. Bettencourt P, Ferreira A, Pardal-Oliveira N et al (2000) Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. Clin Cardiol 23:921–927

    PubMed  CAS  Google Scholar 

  141. Choy AM, Darbar D, Lang CC et al (1994) Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 72:16–22

    PubMed  CAS  Google Scholar 

  142. Baruch L, Glazer RD, Aknay N et al (2004) Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 148:951–957

    PubMed  Google Scholar 

  143. Hutcheon SD, Gillespie ND, Struthers AD, McMurdo ME (2002) B-type natriuretic peptide in the diagnosis of elderly day hospital patients. Age Ageing 31:295–301

    PubMed  Google Scholar 

  144. Hedberg P, Lonnberg I, Jonason T et al (2004) Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. Am Heart J 148:524–529

    PubMed  CAS  Google Scholar 

  145. Heidenreich PA, Gubens MA, Fonarow GC et al (2004) Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43:1019–1026

    PubMed  CAS  Google Scholar 

  146. Ray P, Arthaud M, Lefort Y et al (2004) Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med 30:2230–2236

    PubMed  Google Scholar 

  147. Valle R, Aspromonte N, Barro S et al (2005) The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. Eur J Heart Fail 7:542–551

    PubMed  CAS  Google Scholar 

  148. Suzuki T, Hayashi D, Yamazaki T et al (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136:362–363

    PubMed  CAS  Google Scholar 

  149. Nousiainen T, Jantunen E, Vanninen E et al (1998) Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol 61:347–353

    PubMed  CAS  Google Scholar 

  150. Nousiainen T, Jantunen E, Vanninen E et al (1999) Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma. Eur J Haematol 62:135–141

    PubMed  CAS  Google Scholar 

  151. Okumura H, Iuchi K, Yoshida T et al (2000) Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104:158–163

    PubMed  CAS  Google Scholar 

  152. Hayakawa H, Komada Y, Hirayama M et al (2001) Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 37:4–9

    PubMed  CAS  Google Scholar 

  153. Pinarli FG, Oguz A, Sedef Tunaoglu SF et al (2005) Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 44:370–377

    PubMed  Google Scholar 

  154. Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. (Review) Eur J Heart Fail 4:235–242

    PubMed  CAS  Google Scholar 

  155. Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717

    Google Scholar 

  156. Daugaard G, Lassen U, Bie P et al (2005) Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7:87–93

    PubMed  CAS  Google Scholar 

  157. Koh E, Nakamura T, Takahashi H (2004) Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 68:163–167

    PubMed  CAS  Google Scholar 

  158. Cardinale D, Sandri MT, Martinoni A et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36:517–522

    PubMed  CAS  Google Scholar 

  159. Sandri MT, Cardinale D, Zorzino L et al (2003) Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 49:248–252

    PubMed  CAS  Google Scholar 

  160. Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749–2754

    PubMed  CAS  Google Scholar 

  161. Pichon MF, Cvitkovic F, Hacene K et al (2005) Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In vivo 19:567–576

    PubMed  CAS  Google Scholar 

  162. Sandri MT, Salvatici M, Cardinale D et al (2005) N-Terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 51:1405–1410

    PubMed  CAS  Google Scholar 

  163. Foote RS, Pearlman JD, Siegel AH, Yeo KT (2004) Detection of exercise-induced ischemia by changes in B-type natriuretic peptide. J Am Coll Cardiol 44:1980–1987

    PubMed  CAS  Google Scholar 

  164. Sabatine MS, Morrow DA, de Lemos JA et al (2004) TIMI Study Group. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 44:1988–1995

    PubMed  CAS  Google Scholar 

  165. Gianrossi R, Detrano R, Mulvihill D et al (1989) Exercise-induced ST depression in the diagnosis of coronary artery disease: a meta-analysis. Circulation 80:87–98

    PubMed  CAS  Google Scholar 

  166. Froelicher VF, Lehmann KG, Thomas R et al (1998) The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction: Veterans Affairs Cooperative Study in Health Services #016 (QUEXTA) Study Group. Quantitative exercise testing and angiography. Ann Intern Med 128:965–974

    PubMed  CAS  Google Scholar 

  167. Morise AP, Diamond GA (1995) Comparison of the sensitivity and specificity of exercise electrocardiography in biased and unbiased populations of men and women. Am Heart J 130:741–747

    PubMed  CAS  Google Scholar 

  168. Cardarelli R, Lumicao TG (2003) B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. (Review) J Am Board Fam Pract 16:327–333

    PubMed  Google Scholar 

  169. Davie AP, Francis CM, Love MP et al (1996) Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. Br Med J 312:222

    CAS  Google Scholar 

  170. Ogawa K, Oida A, Sugimura H et al (2002) Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients: comparison of electrocardiography, chest radiography and echocardiography. Circ J 66:122–126

    PubMed  CAS  Google Scholar 

  171. Ng LL, Loke I, Davies JE et al (2003) Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Eur J Heart Fail 5:775–782

    PubMed  CAS  Google Scholar 

  172. Hedberg P, Lonnberg I, Jonason T et al (2004) Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. Am Heart J 148:524–529

    PubMed  CAS  Google Scholar 

  173. Talwar S, Squire IB, Davies JE et al (1999) Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J 20:1736–1744

    PubMed  CAS  Google Scholar 

  174. Nakamura M, Sakai T, Osawa M et al (2005) Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. Int Heart J 46:477–487

    PubMed  CAS  Google Scholar 

  175. Struthers AD (1993) Plasma concentrations of brain natriuretic peptide: will this new test reduce the need for cardiac investigations? (Editorial) Br Heart J 70:397–398

    PubMed  CAS  Google Scholar 

  176. Thomas MD, Fox KF, Coats AJ, Sutton GC (2004) The epidemiological enigma of heart failure with preserved systolic function. Eur J Heart Fail 6:125–136

    PubMed  Google Scholar 

  177. Choy AM, Darbar D, Lang CC et al (1994) Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J 72:16–22

    PubMed  CAS  Google Scholar 

  178. Dokainish H, Zoghbi WA, Lakkis NM et al (2004) Comparative accuracy of B-type natriuretic peptide and tissue Doppler echocardiography in the diagnosis of congestive heart failure. Am J Cardiol 93:1130–1151

    PubMed  CAS  Google Scholar 

  179. Gackowski A, Isnard R, Golmard JL et al (2004) Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 25:1788–1796

    PubMed  CAS  Google Scholar 

  180. Mak GS, DeMaria A, Clopton P, Maisel AS (2004) Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J 148:895–902

    PubMed  CAS  Google Scholar 

  181. Steg PG, Joubin L, McCord J et al (2005) B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 128:21–29

    PubMed  CAS  Google Scholar 

  182. Forfia PR, Watkins SP, Rame JE et al (2005) Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 45:1667–1671

    PubMed  CAS  Google Scholar 

  183. O’Neill JO, Bott-Silverman CE, McRae AT 3rd et al (2005) B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J 149:363–369

    PubMed  CAS  Google Scholar 

  184. Parsonage WA, Galbraith AJ, Koerbin GL, Potter JM (2005) Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 95:883–885

    PubMed  CAS  Google Scholar 

  185. Rodeheffer RJ (2004) Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? (Review) J Am Coll Cardiol 44:740–749

    PubMed  CAS  Google Scholar 

  186. Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. (Review) BMJ 330:625–633

    PubMed  CAS  Google Scholar 

  187. Benedict CR, Shelton B, Johnstone DE et al (1996) Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation 94:690–697

    PubMed  CAS  Google Scholar 

  188. Wallen T, Landahl S, Hedner T et al (1997) Brain natriuretic peptide predicts mortality in the elderly. Heart 77:264–267

    PubMed  CAS  Google Scholar 

  189. Tsutamoto T, Wada A, Maeda K et al (1999) Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 20:1799–1807

    PubMed  CAS  Google Scholar 

  190. Stanek B, Frey B, Hulsmann M et al (2001) Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38:436–442

    PubMed  CAS  Google Scholar 

  191. Anand IS, Fisher LD, Chiang YT et al (2003) Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–1283

    PubMed  CAS  Google Scholar 

  192. Gardner RS, Ozalp F, Murday AJ et al (2003) N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24:1735–1743

    PubMed  CAS  Google Scholar 

  193. Baruch L, Glazer RD, Aknay N et al (2004) Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 148:951–957

    PubMed  Google Scholar 

  194. Kellett J (2004) Prediction of in-hospital mortality by brain natriuretic peptide levels and other independent variables in acutely ill patients with suspected heart disease. Can J Cardiol 20:686–690

    PubMed  Google Scholar 

  195. Kirk V, Bay M, Parner J et al (2004) N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 6:335–341

    PubMed  CAS  Google Scholar 

  196. Berger R, Huelsmann M, Strecker K et al (2005) Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur J Clin Invest 35:24–31

    PubMed  CAS  Google Scholar 

  197. Hulsmann M, Berger R, Mortl D et al (2005) Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: a direct comparison of Nterminal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide. Eur J Heart Fail 7:552–556

    PubMed  Google Scholar 

  198. Segawa T, Nakamura M, Itai K et al (2005) Plasma B-type natriuretic peptide levels and risk factors for congestive heart failure in a Japanese general population. Int Heart J 46:465–475

    PubMed  CAS  Google Scholar 

  199. Stanton E, Hansen M, Wijeysundera HC et al (2005) A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin. Eur J Heart Fail 7:557–565

    PubMed  CAS  Google Scholar 

  200. Bertinchant JP, Combes N, Polge A et al (2005) Prognostic value of cardiac troponin T in patients with both acute and chronic stable congestive heart failure: comparison with atrial natriuretic peptide, brain natriuretic peptide and plasma norepinephrine. Clin Chim Acta 352:143–153

    PubMed  CAS  Google Scholar 

  201. Isnard R, Pousset F, Chafirovskaia O et al (2003) Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J 146:729–735

    PubMed  CAS  Google Scholar 

  202. de Groote P, Dagorn J, Soudan B et al (2004) B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol 43:1584–1589

    PubMed  Google Scholar 

  203. Kyuma M, Nakata T, Hashimoto A et al (2004) Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 45:155–163

    PubMed  CAS  Google Scholar 

  204. Latini R, Masson S, Anand I et al (2004) The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25:292–299

    PubMed  CAS  Google Scholar 

  205. Van Beneden R, Gurne O, Selvais PL et al (2004) Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 10:490–495

    PubMed  Google Scholar 

  206. Berger R, Huelsmann M, Strecker K et al (2005) Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur J Clin Invest 35:24–31

    PubMed  CAS  Google Scholar 

  207. Alehagen U, Dahlstrom U, Lindahl TL (2004) Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 92:1250–1258

    PubMed  CAS  Google Scholar 

  208. Ishii J, Cui W, Kitagawa F et al (2003) Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 49:2020–2026

    PubMed  CAS  Google Scholar 

  209. Fonarow GC, Horwich TB (2003) Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. (Review) Rev Cardiovasc Med 4(suppl 4):S20–28

    PubMed  Google Scholar 

  210. De Mello WC (2004) Heart failure: how important is cellular sequestration? The role of the renin-angiotensin-aldosterone system. (Review) J Mol Cell Cardiol 37:431–438

    PubMed  Google Scholar 

  211. Sekiguchi K, Li X, Coker M et al (2004) Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. (Review) Cardiovasc Res 63:433–442

    PubMed  CAS  Google Scholar 

  212. Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. (Review) Circ Res 94:1543–1553

    PubMed  CAS  Google Scholar 

  213. Kanda T, Takahashi T (2004) Interleukin-6 and cardiovascular diseases. (Review) Jpn Heart J 45:183–193

    PubMed  CAS  Google Scholar 

  214. von Haehling S, Jankowska EA, Anker SD (2004) Tumour necrosis factor-alpha and the failing heart-pathophysiology and therapeutic implications. (Review) Basic Res Cardiol 99:18–28

    Google Scholar 

  215. Moe GW, Rouleau JL, Nguyen QT et al (2003) Role of endothelins in congestive heart failure. (Review) Can J Physiol Pharmacol 81:588–597

    PubMed  CAS  Google Scholar 

  216. Boerrigter G, Burnett JC (2003) Endothelin in neurohormonal activation in heart failure. (Review) Coron Artery Dis 14:495–500

    PubMed  Google Scholar 

  217. Floras JS (2003) Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. (Review) Acta Physiol Scand 177:391–398

    PubMed  CAS  Google Scholar 

  218. Piano MR, Prasun M (2003) Neurohormone activation. (Review) Crit Care Nurs Clin North Am 15:413–421

    PubMed  Google Scholar 

  219. Ascheim DD, Hryniewicz K (2002) Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid 12:511–515

    PubMed  CAS  Google Scholar 

  220. Danzi S, Klein I (2004) Thyroid hormone and the cardiovascular system. (Review) Minerva Endocrinol 29:139–150

    PubMed  CAS  Google Scholar 

  221. Myocardial infarction redefined (2000)-a consensus document of the Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959–969

    Google Scholar 

  222. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction (2002) A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). American College of Cardiology and the American Heart Association, Inc, pp 1–95

    Google Scholar 

  223. Omland T, Persson A, Ng L et al (2002) N-terminal pro-B-type natriuretic peptide and longterm mortality in acute coronary syndromes. Circulation 106:2913–2918

    PubMed  CAS  Google Scholar 

  224. Arakawa N, Nakamura M, Aoki H, Hiramori K (1996) Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol 27:1656–1661

    PubMed  CAS  Google Scholar 

  225. Darbar D, Davidson NC, Gillespie N et al (1996) Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol 78:284–287

    PubMed  CAS  Google Scholar 

  226. Crilley JG, Farrer M (2001) Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart 86:638–642

    PubMed  CAS  Google Scholar 

  227. McDonagh TA, Cunningham AD, Morrison CE et al (2001) Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 86:21–26

    PubMed  CAS  Google Scholar 

  228. Richards AM, Doughty R, Nicholls MG et al (2001) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37:1781–1787

    PubMed  CAS  Google Scholar 

  229. Inoue T, Sakuma M, Yaguchi I et al (2002) Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Am Heart J 143:790–796

    PubMed  CAS  Google Scholar 

  230. Sabatine MS, Morrow DA, de Lemos JA et al (2002) Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 105:1760–1763

    PubMed  CAS  Google Scholar 

  231. Jernberg T, Stridsberg M, Lindahl B (2002) Usefulness of plasma N-terminal proatrial natriuretic peptide (proANP) as an early predictor of outcome in unstable angina pectoris or non-ST-elevation acute myocardial infarction. Am J Cardiol 89:64–66

    PubMed  CAS  Google Scholar 

  232. Jernberg T, Stridsberg M, Venge P, Lindahl B (2002) N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40:437–445

    PubMed  CAS  Google Scholar 

  233. Heeschen C, Hamm CW, Mitrovic V et al (2004) Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110:3206–3212

    PubMed  CAS  Google Scholar 

  234. Jernberg T, James S, Lindahl B et al (2004) NT-proBNP in unstable coronary artery disease-experiences from the FAST, GUSTO IV and FRISC II trials. Eur J Heart Fail 6:319–325

    PubMed  CAS  Google Scholar 

  235. Mega JL, Morrow DA, De Lemos JA et al (2004) B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRETIMI-23 substudy. J Am Coll Cardiol 44:335–339

    PubMed  CAS  Google Scholar 

  236. Palazzuoli A, Calabria P, Vecchiato L et al (2004) Plasma brain natriuretic peptide levels in coronary heart disease with preserved systolic function. Clin Exp Med 4:44–49

    PubMed  CAS  Google Scholar 

  237. Squire IB, O’Brien RJ, Demme B et al (2004) N-terminal pro-atrial natriuretic peptide (NANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci 107:309–316

    PubMed  CAS  Google Scholar 

  238. Suzuki S, Yoshimura M, Nakayama M et al (2004) Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation 110:1387–1391

    PubMed  CAS  Google Scholar 

  239. Wylie JV, Murphy SA, Morrow DA et al (2004) Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. Am Heart J 148:173–180

    PubMed  Google Scholar 

  240. Squire IB, Orn S, Ng LL et al (2005) Plasma natriuretic peptides up to 2 years after acute myocardial infarction and relation to orognosis: an OPTIMAAL substudy. J Card Fail 11:492–497

    PubMed  CAS  Google Scholar 

  241. Omland T, Richards AM, Wergeland R, Vik-Mo H (2005) B-type natriuretic peptide and longterm survival in patients with stable coronary artery disease. Am J Cardiol 95:24–28

    PubMed  CAS  Google Scholar 

  242. Kragelund C, Gronning B, Kober L et al (2005) N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352:666–675

    PubMed  CAS  Google Scholar 

  243. Hama N, Itoh H, Shirakami G et al (1995) Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92:1158–1164

    Google Scholar 

  244. Toth M, Vuorinen KH, Vuolteenaho O et al (1994) Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol 266(4 Pt 2):H1572–1580

    PubMed  CAS  Google Scholar 

  245. Goetze JP, Gore A, Moller CH et al (2004) Acute myocardial hypoxia increases BNP gene expression. FASEB J 18:1928–1930

    PubMed  CAS  Google Scholar 

  246. Marumoto K, Hamada M, Hiwada K (1995) Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci 88:551–556

    PubMed  CAS  Google Scholar 

  247. Dyrbye LN, Redfield MM (2003) The role of brain natriuretic peptide in population screening. Heart Fail Rev 8:349–354

    PubMed  CAS  Google Scholar 

  248. Freitag MH, Vasan RS (2003) Screening for left ventricular systolic dysfunction: the use of Btype natriuretic peptide. Heart Fail Monit 4:38–44

    PubMed  Google Scholar 

  249. Davis KM, Fish LC, Elahi D et al (1992) Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly. JAMA 267:2625–2629

    PubMed  CAS  Google Scholar 

  250. Knight EL, Fish LC, Kiely DK et al (1999) Atrial natriuretic peptide and the development of congestive heart failure in the oldest old: a seven-year prospective study. J Am Geriatr Soc 47:407–411

    PubMed  CAS  Google Scholar 

  251. Freitag MH, Larson MG, Levy D et al (2003) Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension 41:978–983

    PubMed  CAS  Google Scholar 

  252. Murdoch DR, McDonagh TA, Byrne J et al (1999) Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138:1126–1132

    PubMed  CAS  Google Scholar 

  253. Troughton RW, Frampton CM, Yandle TG et al (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130

    PubMed  CAS  Google Scholar 

  254. Kawai K, Hata K, Takaoka H et al (2001) Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J 141:925–932

    PubMed  CAS  Google Scholar 

  255. Maisel AS (2001) B-type natriuretic peptide (BNP) levels: diagnostic and therapeutic potential. (Review) Rev Cardiovasc Med 2(suppl 2):S13–18

    PubMed  Google Scholar 

  256. Nicholls MG, Lainchbury JG, Richards AM et al (2001) Brain natriuretic peptide-guided therapy for heart failure. Ann Med 33:422–427

    PubMed  CAS  Google Scholar 

  257. Troughton RW, Richards AM, Nicholls MG (2001) Individualized treatment of heart failure. Intern Med J 31:138–141

    PubMed  CAS  Google Scholar 

  258. McGeoch G, Lainchbury J, Town GI et al (2002) Plasma brain natriuretic peptide after longterm treatment for heart failure in general practice. Eur J Heart Fail 4:479–483

    PubMed  CAS  Google Scholar 

  259. Mueller C, Buser P (2002) B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure? (Review) Swiss Med Wkly 132:618–622

    PubMed  CAS  Google Scholar 

  260. Hobbs RE (2003) Using BNP to diagnose, manage, and treat heart failure. (Review) Cleve Clin J Med 70:333–336

    PubMed  Google Scholar 

  261. Richards M (2003) Outpatient management of heart failure. (Review) Heart Fail Rev 8:345–348

    PubMed  CAS  Google Scholar 

  262. Maisel A, Hollander JE, Guss D et al (2004) Rapid Emergency Department Heart Failure Outpatient Trial investigators. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44:1328–1333

    PubMed  Google Scholar 

  263. Morimoto T, Hayashino Y, Shimbo T et al (2004) Is B-type natriuretic peptide-guided heart failure management cost-effective? Int J Cardiol 96:177–181

    PubMed  Google Scholar 

  264. Wu AH, Harrison A, Maisel AS (2004) Reduced readmission rate for alternating diagnoses of heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing. Eur J Heart Fail 6:309–312

    PubMed  CAS  Google Scholar 

  265. Mueller C, Scholer A, Laule-Kilian K et al (2004) Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 350:647–654

    PubMed  CAS  Google Scholar 

  266. Kirchhoff WCh, Gradaus R, Stypmann J et al (2004) Vasoactive peptides during long-term follow-up of patients after cardiac transplantation. J Heart Lung Transplant 23:284–288

    PubMed  Google Scholar 

  267. Kemperman H, van den Berg M, Kirkels H, de Jonge N (2004) B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem 50:1670–1672

    PubMed  CAS  Google Scholar 

  268. Thompson LO, Skrabal CA, Loebe M et al (2005) Plasma neurohormone levels correlate with left ventricular functional and morphological improvement in LVAD patients. J Surg Res 123:25–32

    PubMed  CAS  Google Scholar 

  269. Crozier IG, Nicholls MG, Ikram H et al (1989) Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition. Clin Exp Pharmacol Physiol 16:417–424

    PubMed  CAS  Google Scholar 

  270. Yoshimura M, Yasue H, Tanaka H et al (1994) Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 72:528–533

    PubMed  CAS  Google Scholar 

  271. Davidson NC, Coutie WJ, Webb DJ, Struthers AD (1996) Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart 75:576–581

    PubMed  CAS  Google Scholar 

  272. Nishikimi T, Matsuoka H, Ishikawa K et al (1996) Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension. Hypertens Res 19:97–101

    PubMed  CAS  Google Scholar 

  273. Missouris CG, Grouzmann E, Buckley MG et al (1998) How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. Clin Sci 94:591–599

    PubMed  CAS  Google Scholar 

  274. Hara Y, Hamada M, Shigematsu Y et al (2000) Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensinconverting enzyme inhibitor. Jpn Circ J 64:365–369

    PubMed  CAS  Google Scholar 

  275. Tsutamoto T, Wada A, Maeda K et al (2001) Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37:1228–1233

    PubMed  CAS  Google Scholar 

  276. Johnson W, Omland T, Hall C et al (2002) Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 39:1623–1629

    PubMed  CAS  Google Scholar 

  277. Cotter G, Kaluski E, Stangl K et al (2004) The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 6:601–609

    PubMed  CAS  Google Scholar 

  278. Bouissou P, Galen FX, Richalet JP et al (1989) Effects of propranolol and pindolol on plasma ANP levels in humans at rest and during exercise. Am J Physiol 257:R259–264

    PubMed  CAS  Google Scholar 

  279. Colantonio D, Casale R, Desiati P et al (1991) Short-term effects of atenolol and nifedipine on atrial natriuretic peptide, plasma renin activity, and plasma aldosterone in patients with essential hypertension. J Clin Pharmacol 31:238–242

    PubMed  CAS  Google Scholar 

  280. Yoshimura M, Yasue H, Tanaka H et al (1994) Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 72:528–533

    PubMed  CAS  Google Scholar 

  281. Sanderson JE, Chan WW, Hung YT et al (1995) Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 74:502–507

    PubMed  CAS  Google Scholar 

  282. Luchner A, Burnett JC Jr, Jougasaki M et al (1998) Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 32:1839–1844

    PubMed  CAS  Google Scholar 

  283. Fujimura M, Yasumura Y, Ishida Y et al (2000) Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail 6:3–10

    PubMed  CAS  Google Scholar 

  284. Hara Y, Hamada M, Shigematsu Y et al (2000) Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ J 64:365–369

    PubMed  CAS  Google Scholar 

  285. Hirooka K, Yasumura Y, Ishida Y et al (2001) Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy. Jpn Circ J 65:931–936

    PubMed  CAS  Google Scholar 

  286. Kawai K, Hata K, Takaoka H et al (2001) Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J 141:925–932

    PubMed  CAS  Google Scholar 

  287. Hara Y, Hamada M, Ohtsuka T et al (2002) Comparison of treatment effects of bevantolol and metoprolol on cardiac function and natriuretic peptides in patients with dilated cardiomyopathy. Heart Vessels 17:53–56

    PubMed  Google Scholar 

  288. Persson H, Andreasson K, Kahan T et al (2002) Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail 4:73–82

    PubMed  CAS  Google Scholar 

  289. Fung JW, Yu CM, Yip G et al (2003) Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92:406–410

    PubMed  CAS  Google Scholar 

  290. Konishi H, Nishio S, Tsutamoto T et al (2003) Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study. Int J Clin Pharmacol Ther 41:578–586

    PubMed  CAS  Google Scholar 

  291. van den Meiracker AH, Lameris TW, van de Ven LL, Boomsma F (2003) Increased plasma concentration of natriuretic peptides by selective beta1-blocker bisoprolol. J Cardiovasc Pharmacol 42:462–468

    PubMed  Google Scholar 

  292. Yoshizawa A, Yoshikawa T, Nakamura I et al (2004) Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure. J Card Fail 10:310–315

    PubMed  CAS  Google Scholar 

  293. Ohta Y, Watanabe K, Nakazawa M et al (2000) Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol 36(suppl 2):S19–23

    PubMed  CAS  Google Scholar 

  294. Beck-da-Silva L, de Bold A, Fraser M et al (2005) BNP-guided therapy not better than expert’s clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail 11:248–253

    PubMed  CAS  Google Scholar 

  295. Lewin J, Ledwidge M, O’loughlin C et al (2005) Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis? Eur J Heart Fail 7:953–957

    PubMed  CAS  Google Scholar 

  296. Emdin M, Clerico A, Clemenza F et al (2005) Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 6:430–446

    PubMed  Google Scholar 

  297. Jourdain P, Gueffet P, Le Helloco J et al (2005) STARS-BNP Investigators on behalf of the working group on Heart failure of the French Society of Cardiology. Benefit of BNP plasma levels for optimising therapy in patients with systolic heart failure. Supported by STARSBNP multicenter randomised study. Eur J Heart Failure 4(suppl 1):120

    Google Scholar 

  298. Clerico A, Recchia FA, Passino C, Emdin M (2006) Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 290:H17–29

    PubMed  CAS  Google Scholar 

  299. Nieminen MS, Bohm M, Cowie MR et al (2005) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 26:384–416

    PubMed  Google Scholar 

  300. Swedberg K, Cleland J, Dargie H et al (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26:1115–1140

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cardiovascular Endocrinology and Cell Biology, CNR Institute of Clinical Physiology, G Pasquinucci Hospital, Italy

    Aldo Clerico MD (Director)

  2. Cardiovascular Medicine Department, CNR Institute of Clinical Physiology, Pisa

    Claudio Passino MD (Researcher) & Michele Emdin MD, PhD (Head)

Authors
  1. Aldo Clerico MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudio Passino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michele Emdin MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Laboratory Medicine Institute of Clinical Physiology, CNR - National Research Council, Pisa, Italy

    Aldo Clerico  & Michele Emdin  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

Clerico, A., Passino, C., Emdin, M. (2006). Clinical Considerations and Applications in Cardiac Diseases. In: Clerico, A., Emdin, M. (eds) Natriuretic Peptides. Springer, Milano. https://doi.org/10.1007/88-470-0498-5_5

Download citation

  • DOI: https://doi.org/10.1007/88-470-0498-5_5

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0497-9

  • Online ISBN: 978-88-470-0498-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation